209 related articles for article (PubMed ID: 31764406)
21. Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma.
Kim Y; Lee HA; Lee JS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Um SH; Seo YS; Kim SU
Cancer Invest; 2021 Mar; 39(3):274-283. PubMed ID: 33356630
[TBL] [Abstract][Full Text] [Related]
22. Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization.
Kim Y; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
Curr Oncol; 2021 Feb; 28(1):965-977. PubMed ID: 33617513
[TBL] [Abstract][Full Text] [Related]
23. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
[TBL] [Abstract][Full Text] [Related]
24. Quantitative Imaging Biomarkers for
Schobert I; Chapiro J; Nezami N; Hamm CA; Gebauer B; Lin M; Pollak J; Saperstein L; Schlachter T; Savic LJ
J Nucl Med; 2019 Aug; 60(8):1066-1072. PubMed ID: 30655331
[TBL] [Abstract][Full Text] [Related]
25. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
[TBL] [Abstract][Full Text] [Related]
26. Tumor Size and Watershed Area Correlate with Incomplete Treatment and Tumor Progression after Selective Radioembolization for Hepatocellular Carcinoma.
Yu Q; Neale M; Ungchusri E; Rothenberger NJ; Liao C; Patel M; Pillai A; Navuluri R; Ahmed O; Ha TV
J Vasc Interv Radiol; 2024 May; 35(5):712-721.e3. PubMed ID: 38336031
[TBL] [Abstract][Full Text] [Related]
27. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience.
Tohme S; Sukato D; Chen HW; Amesur N; Zajko AB; Humar A; Geller DA; Marsh JW; Tsung A
J Vasc Interv Radiol; 2013 Nov; 24(11):1632-8. PubMed ID: 24160821
[TBL] [Abstract][Full Text] [Related]
28. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
Kallini JR; Gabr A; Salem R; Lewandowski RJ
Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186
[TBL] [Abstract][Full Text] [Related]
29. Safety of Radioembolization in the Setting of Angiographically Apparent Arterioportal Shunting.
Thornton LM; Geller BS; Pepin EW; Shah JL; Kapp M; Toskich BB
J Vasc Interv Radiol; 2018 Nov; 29(11):1511-1518. PubMed ID: 30293727
[TBL] [Abstract][Full Text] [Related]
30.
Abouchaleh N; Gabr A; Ali R; Al Asadi A; Mora RA; Kallini JR; Mouli S; Riaz A; Lewandowski RJ; Salem R
J Nucl Med; 2018 Jul; 59(7):1042-1048. PubMed ID: 29217739
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of Y90 Radioembolization for Hepatocellular Carcinoma in Patients Previously Treated with Transarterial Embolization.
Zhao K; Son S; Karimi A; Marinelli B; Erinjeri JP; Alexander ES; Sotirchos VS; Harding JJ; Soares KC; Ziv E; Covey A; Sofocleous CT; Yarmohammadi H
Curr Oncol; 2024 May; 31(5):2650-2661. PubMed ID: 38785481
[TBL] [Abstract][Full Text] [Related]
32. Assessment of HCC response to Yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology.
Vietti Violi N; Gnerre J; Law A; Hectors S; Bane O; Doucette J; Abboud G; Kim E; Schwartz M; Fiel MI; Taouli B
Eur Radiol; 2022 Sep; 32(9):6493-6503. PubMed ID: 35380226
[TBL] [Abstract][Full Text] [Related]
33. Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients.
Saxena A; Meteling B; Kapoor J; Golani S; Danta M; Morris DL; Bester L
Int J Surg; 2014 Dec; 12(12):1403-8. PubMed ID: 25091398
[TBL] [Abstract][Full Text] [Related]
34. Histological changes in nontumoral liver secondary to radioembolization of hepatocellular carcinoma with yttrium 90-impregnated microspheres: report of two cases.
Dhingra S; Schwartz M; Kim E; Mabel Ko H; Ward SC; Fiel MI; Thung SN
Semin Liver Dis; 2014 Nov; 34(4):465-8. PubMed ID: 25369308
[TBL] [Abstract][Full Text] [Related]
35. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
[TBL] [Abstract][Full Text] [Related]
36. Resin Versus Glass Microspheres for
Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
[TBL] [Abstract][Full Text] [Related]
37. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib.
Teyateeti A; Mahvash A; Long J; Abdelsalam M; Avritscher R; Kaseb A; Odisio B; Ravizzini G; Surasi D; Teyateeti A; Macapinlac H; Kappadath SC
World J Gastroenterol; 2021 Dec; 27(47):8166-8181. PubMed ID: 35068861
[TBL] [Abstract][Full Text] [Related]
38. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
[TBL] [Abstract][Full Text] [Related]
39. The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization.
Sukato DC; Tohme S; Chalhoub D; Han K; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A
J Vasc Interv Radiol; 2015 Jun; 26(6):816-24.e1. PubMed ID: 25824315
[TBL] [Abstract][Full Text] [Related]
40. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization.
Xing M; Kokabi N; Camacho JC; Kim HS
BMC Cancer; 2018 Jan; 18(1):75. PubMed ID: 29329568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
